S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
pixel
Log in
NASDAQ:OMCL

Omnicell Competitors

$129.40
+2.50 (+1.97 %)
(As of 03/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$127.51
Now: $129.40
$130.74
50-Day Range
$117.78
MA: $125.80
$133.80
52-Week Range
$54.24
Now: $129.40
$137.99
Volume197,076 shs
Average Volume358,118 shs
Market Capitalization$5.57 billion
P/E Ratio148.74
Dividend YieldN/A
Beta1.04

Competitors

Omnicell (NASDAQ:OMCL) Vs. CERN, ABC, WST, HZNP, FMS, and CTLT

Should you be buying OMCL stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Omnicell, including Cerner (CERN), AmerisourceBergen (ABC), West Pharmaceutical Services (WST), Horizon Therapeutics Public (HZNP), Fresenius Medical Care AG & Co. KGaA (FMS), and Catalent (CTLT).

Cerner (NASDAQ:CERN) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.

Profitability

This table compares Cerner and Omnicell's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cerner14.28%18.14%10.81%
Omnicell4.25%7.96%5.19%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Cerner and Omnicell, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cerner251002.47
Omnicell02502.71

Cerner currently has a consensus price target of $79.7778, indicating a potential upside of 13.72%. Omnicell has a consensus price target of $116.3333, indicating a potential downside of 10.10%. Given Cerner's higher possible upside, equities research analysts plainly believe Cerner is more favorable than Omnicell.

Valuation & Earnings

This table compares Cerner and Omnicell's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cerner$5.69 billion3.77$529.45 million$2.4129.11
Omnicell$897.03 million6.21$61.34 million$2.1959.09

Cerner has higher revenue and earnings than Omnicell. Cerner is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

83.0% of Cerner shares are held by institutional investors. Comparatively, 99.2% of Omnicell shares are held by institutional investors. 0.3% of Cerner shares are held by insiders. Comparatively, 2.6% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Cerner has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Summary

Cerner beats Omnicell on 8 of the 14 factors compared between the two stocks.

AmerisourceBergen (NYSE:ABC) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.

Profitability

This table compares AmerisourceBergen and Omnicell's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AmerisourceBergen-1.80%65.93%3.91%
Omnicell4.25%7.96%5.19%

Analyst Recommendations

This is a summary of recent recommendations and price targets for AmerisourceBergen and Omnicell, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AmerisourceBergen03702.70
Omnicell02502.71

AmerisourceBergen currently has a consensus price target of $121.1111, indicating a potential upside of 17.39%. Omnicell has a consensus price target of $116.3333, indicating a potential downside of 10.10%. Given AmerisourceBergen's higher possible upside, equities research analysts plainly believe AmerisourceBergen is more favorable than Omnicell.

Valuation & Earnings

This table compares AmerisourceBergen and Omnicell's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AmerisourceBergen$189.89 billion0.11$-3,408,720,000.00$7.9013.06
Omnicell$897.03 million6.21$61.34 million$2.1959.09

Omnicell has lower revenue, but higher earnings than AmerisourceBergen. AmerisourceBergen is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

63.4% of AmerisourceBergen shares are held by institutional investors. Comparatively, 99.2% of Omnicell shares are held by institutional investors. 28.3% of AmerisourceBergen shares are held by insiders. Comparatively, 2.6% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

AmerisourceBergen has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Summary

Omnicell beats AmerisourceBergen on 8 of the 14 factors compared between the two stocks.

West Pharmaceutical Services (NYSE:WST) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, profitability, risk and analyst recommendations.

Insider & Institutional Ownership

92.6% of West Pharmaceutical Services shares are held by institutional investors. Comparatively, 99.2% of Omnicell shares are held by institutional investors. 1.6% of West Pharmaceutical Services shares are held by insiders. Comparatively, 2.6% of Omnicell shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares West Pharmaceutical Services and Omnicell's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
West Pharmaceutical Services14.69%19.01%12.78%
Omnicell4.25%7.96%5.19%

Valuation & Earnings

This table compares West Pharmaceutical Services and Omnicell's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$1.84 billion11.40$241.70 million$3.2487.34
Omnicell$897.03 million6.21$61.34 million$2.1959.09

West Pharmaceutical Services has higher revenue and earnings than Omnicell. Omnicell is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for West Pharmaceutical Services and Omnicell, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
West Pharmaceutical Services01202.67
Omnicell02502.71

West Pharmaceutical Services currently has a consensus price target of $310.00, indicating a potential upside of 9.54%. Omnicell has a consensus price target of $116.3333, indicating a potential downside of 10.10%. Given West Pharmaceutical Services' higher possible upside, equities research analysts plainly believe West Pharmaceutical Services is more favorable than Omnicell.

Volatility and Risk

West Pharmaceutical Services has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 1.04, meaning that its share price is 4% more volatile than the S&P 500.

Summary

West Pharmaceutical Services beats Omnicell on 9 of the 14 factors compared between the two stocks.

Horizon Therapeutics Public (NASDAQ:HZNP) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

88.6% of Horizon Therapeutics Public shares are held by institutional investors. Comparatively, 99.2% of Omnicell shares are held by institutional investors. 4.3% of Horizon Therapeutics Public shares are held by company insiders. Comparatively, 2.6% of Omnicell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Horizon Therapeutics Public and Omnicell's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Horizon Therapeutics Public43.55%25.66%14.19%
Omnicell4.25%7.96%5.19%

Earnings and Valuation

This table compares Horizon Therapeutics Public and Omnicell's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Horizon Therapeutics Public$1.30 billion15.84$573.02 million$1.9447.38
Omnicell$897.03 million6.21$61.34 million$2.1959.09

Horizon Therapeutics Public has higher revenue and earnings than Omnicell. Horizon Therapeutics Public is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Horizon Therapeutics Public and Omnicell, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Horizon Therapeutics Public00803.00
Omnicell02502.71

Horizon Therapeutics Public presently has a consensus price target of $101.8889, indicating a potential upside of 10.86%. Omnicell has a consensus price target of $116.3333, indicating a potential downside of 10.10%. Given Horizon Therapeutics Public's stronger consensus rating and higher possible upside, research analysts clearly believe Horizon Therapeutics Public is more favorable than Omnicell.

Risk & Volatility

Horizon Therapeutics Public has a beta of 1.15, suggesting that its stock price is 15% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.

Summary

Horizon Therapeutics Public beats Omnicell on 11 of the 14 factors compared between the two stocks.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

1.6% of Fresenius Medical Care AG & Co. KGaA shares are held by institutional investors. Comparatively, 99.2% of Omnicell shares are held by institutional investors. 2.6% of Omnicell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Fresenius Medical Care AG & Co. KGaA and Omnicell's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fresenius Medical Care AG & Co. KGaA7.38%10.62%4.15%
Omnicell4.25%7.96%5.19%

Earnings and Valuation

This table compares Fresenius Medical Care AG & Co. KGaA and Omnicell's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fresenius Medical Care AG & Co. KGaA$19.58 billion1.05$1.34 billion$2.5313.85
Omnicell$897.03 million6.21$61.34 million$2.1959.09

Fresenius Medical Care AG & Co. KGaA has higher revenue and earnings than Omnicell. Fresenius Medical Care AG & Co. KGaA is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Fresenius Medical Care AG & Co. KGaA and Omnicell, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fresenius Medical Care AG & Co. KGaA19702.35
Omnicell02502.71

Fresenius Medical Care AG & Co. KGaA presently has a consensus price target of $45.00, indicating a potential upside of 28.42%. Omnicell has a consensus price target of $116.3333, indicating a potential downside of 10.10%. Given Fresenius Medical Care AG & Co. KGaA's higher possible upside, research analysts clearly believe Fresenius Medical Care AG & Co. KGaA is more favorable than Omnicell.

Risk & Volatility

Fresenius Medical Care AG & Co. KGaA has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.

Summary

Fresenius Medical Care AG & Co. KGaA beats Omnicell on 8 of the 14 factors compared between the two stocks.

Catalent (NYSE:CTLT) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

97.8% of Catalent shares are held by institutional investors. Comparatively, 99.2% of Omnicell shares are held by institutional investors. 1.0% of Catalent shares are held by company insiders. Comparatively, 2.6% of Omnicell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Catalent and Omnicell's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Catalent9.25%14.20%4.83%
Omnicell4.25%7.96%5.19%

Earnings and Valuation

This table compares Catalent and Omnicell's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Catalent$3.09 billion6.40$173 million$1.8861.91
Omnicell$897.03 million6.21$61.34 million$2.1959.09

Catalent has higher revenue and earnings than Omnicell. Omnicell is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and target prices for Catalent and Omnicell, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Catalent01702.88
Omnicell02502.71

Catalent presently has a consensus price target of $121.3750, indicating a potential upside of 4.27%. Omnicell has a consensus price target of $116.3333, indicating a potential downside of 10.10%. Given Catalent's stronger consensus rating and higher possible upside, research analysts clearly believe Catalent is more favorable than Omnicell.

Risk & Volatility

Catalent has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.

Summary

Catalent beats Omnicell on 9 of the 14 factors compared between the two stocks.


Omnicell Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cerner logo
CERN
Cerner
2.9$70.15+1.4%$21.49 billion$5.69 billion27.40
AmerisourceBergen logo
ABC
AmerisourceBergen
2.1$103.17+1.9%$21.12 billion$189.89 billion-6.14Decrease in Short Interest
West Pharmaceutical Services logo
WST
West Pharmaceutical Services
1.9$282.99+0.8%$20.97 billion$1.84 billion74.67Dividend Announcement
Decrease in Short Interest
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.4$91.91+1.1%$20.59 billion$1.30 billion25.11Earnings Announcement
Insider Selling
Fresenius Medical Care AG & Co. KGaA logo
FMS
Fresenius Medical Care AG & Co. KGaA
1.9$35.04+1.5%$20.52 billion$19.58 billion13.90Analyst Report
Increase in Short Interest
Analyst Revision
Catalent logo
CTLT
Catalent
1.5$116.40+2.3%$19.81 billion$3.09 billion74.14
Hologic logo
HOLX
Hologic
2.1$74.64+3.4%$19.23 billion$3.78 billion17.77Analyst Report
The Cooper Companies logo
COO
The Cooper Companies
1.7$390.85+1.2%$19.21 billion$2.43 billion81.26Upcoming Earnings
Analyst Report
Teleflex logo
TFX
Teleflex
2.0$403.68+1.4%$18.80 billion$2.60 billion51.95Earnings Announcement
Dividend Announcement
Analyst Report
Analyst Revision
10x Genomics logo
TXG
10x Genomics
1.6$186.75+4.7%$18.74 billion$245.89 million-138.33
GDRX
GoodRx
1.2$46.13+3.5%$18.00 billion$388.22 million0.00Gap Down
CureVac logo
CVAC
CureVac
0.6$96.18+2.0%$17.98 billionN/A0.00Decrease in Short Interest
BIO.B
Bio-Rad Laboratories
0.7$600.70+0.0%$17.92 billion$2.31 billion5.14
Insulet logo
PODD
Insulet
1.3$270.26+4.1%$17.86 billion$738.20 million614.24Earnings Announcement
Analyst Revision
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.3$597.30+2.1%$17.83 billion$2.31 billion5.11
Incyte logo
INCY
Incyte
1.9$79.63+1.2%$17.51 billion$2.16 billion-50.72
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.6$148.75+0.4%$17.40 billion$219.75 million-19.00Analyst Report
Smith & Nephew logo
SNN
Smith & Nephew
2.0$39.11+0.7%$17.15 billion$5.14 billion19.17Dividend Increase
Analyst Downgrade
News Coverage
Avantor logo
AVTR
Avantor
1.8$28.47+2.1%$16.54 billion$6.04 billion237.25
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$175.91+0.4%$16.16 billion$3.17 billion60.04Analyst Downgrade
argenx logo
ARGX
argenx
1.1$340.53+2.9%$16.12 billion$78.17 million-71.99Upcoming Earnings
Elanco Animal Health logo
ELAN
Elanco Animal Health
1.4$33.65+2.3%$15.88 billion$3.07 billion-59.04Earnings Announcement
Analyst Upgrade
Unusual Options Activity
Analyst Revision
Quest Diagnostics logo
DGX
Quest Diagnostics
2.1$116.57+0.8%$15.56 billion$7.73 billion14.41
NovoCure logo
NVCR
NovoCure
1.5$152.43+2.2%$15.52 billion$351.32 million802.31Earnings Announcement
Analyst Report
Analyst Revision
Cardinal Health logo
CAH
Cardinal Health
2.6$52.75+2.3%$15.49 billion$152.92 billion15.94Increase in Short Interest
Novavax logo
NVAX
Novavax
1.2$240.29+3.8%$15.30 billion$18.66 million-46.03Earnings Announcement
Gap Down
Guardant Health logo
GH
Guardant Health
1.7$152.14+3.3%$15.21 billion$214.38 million-79.65Earnings Announcement
Analyst Report
Analyst Revision
STERIS logo
STE
STERIS
2.3$177.77+1.7%$15.17 billion$3.03 billion36.06
Abiomed logo
ABMD
Abiomed
1.5$324.26+0.1%$14.67 billion$840.88 million71.27
Bio-Techne logo
TECH
Bio-Techne
1.8$372.44+2.9%$14.45 billion$738.69 million59.59Analyst Upgrade
Gap Down
Charles River Laboratories International logo
CRL
Charles River Laboratories International
1.5$289.61+1.2%$14.42 billion$2.62 billion48.27Analyst Downgrade
Insider Selling
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$79.17+2.2%$14.37 billion$1.70 billion18.12Earnings Announcement
Analyst Report
Masimo logo
MASI
Masimo
1.4$256.08+2.1%$14.15 billion$937.84 million66.51Earnings Announcement
Analyst Revision
Canopy Growth logo
CGC
Canopy Growth
0.8$34.73+5.7%$13.05 billion$297.34 million-10.40Decrease in Short Interest
Analyst Revision
Gap Down
DENTSPLY SIRONA logo
XRAY
DENTSPLY SIRONA
2.0$59.71+11.1%$13.05 billion$4.03 billion-259.61Earnings Announcement
Dividend Announcement
Analyst Report
High Trading Volume
News Coverage
Gap Down
Molina Healthcare logo
MOH
Molina Healthcare
1.5$222.24+2.5%$12.89 billion$16.83 billion16.66
Oak Street Health logo
OSH
Oak Street Health
2.1$51.97+2.0%$12.51 billionN/A0.00Insider Selling
PPD logo
PPD
PPD
1.7$35.52+1.3%$12.42 billion$4.03 billion236.80Earnings Announcement
Increase in Short Interest
Analyst Revision
Repligen logo
RGEN
Repligen
1.5$221.73+4.2%$12.14 billion$270.24 million270.40Earnings Announcement
Analyst Revision
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.4$10.92+1.5%$11.93 billion$16.89 billion-2.97Gap Down
QIAGEN logo
QGEN
QIAGEN
1.7$50.36+0.7%$11.47 billion$1.53 billion62.17
Grifols logo
GRFS
Grifols
1.2$16.48+1.3%$11.33 billion$5.71 billion14.71
Bausch Health Companies logo
BHC
Bausch Health Companies
1.7$31.75+1.0%$11.28 billion$8.60 billion-5.83Earnings Announcement
Analyst Report
Analyst Revision
DaVita logo
DVA
DaVita
2.0$102.85+0.7%$11.25 billion$11.39 billion15.42
Universal Health Services logo
UHS
Universal Health Services
1.5$127.90+2.0%$10.87 billion$11.38 billion12.54Earnings Announcement
Dividend Announcement
Increase in Short Interest
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
1.6$71.91+1.7%$10.70 billion$40.56 million-21.09Earnings Announcement
Analyst Revision
News Coverage
Gap Down
Penumbra logo
PEN
Penumbra
1.5$291.43+2.4%$10.62 billion$547.41 million-1,079.37Earnings Announcement
Analyst Revision
Natera logo
NTRA
Natera
1.5$123.49+6.0%$10.54 billion$302.33 million-51.89Earnings Announcement
Analyst Report
ABCL
AbCellera Biologics
1.7$39.69+5.0%$10.54 billionN/A0.00Decrease in Short Interest
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.1$109.43+0.1%$10.28 billion$788.10 million117.67Analyst Revision
This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.